Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus
World Journal of Diabetes · 15.03.2024 · 15 (3) · 331-347
DOI: 10.4239/wjd.v15.i3.331 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift World Journal of Diabetes, online erschienen am 15.03.2024. Verfasst von Saleh Fahad Alqifari und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia. salqifari@ut.edu.sa. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
In 2005, exenatide became the first approved glucagon-like peptide-1 receptor agonist (GLP-1 RA) for type 2 diabetes mellitus (T2DM). Since then, numerous GLP-1 RAs have been approved, including tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA, which was approved in 2022. This class of drugs is considered safe with no hypoglycemia risk, making it a common second-line choice after metformin for treating T2DM. Various considerations can make selecting and switching between different GLP-1 RAs challenging. Our study aims to provide a comprehensive guide for the usage of GLP-1 RAs and dual GIP and GLP-1 RAs for the management of T2DM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia. salqifari@ut.edu.sa.
- Department of Clinical Sciences, Sulaiman Alrajhi University - College of Medicine, Al Bukayriyah 52726, Saudi Arabia.
- Department of Family Medicine, Dr. Soliman Fakeeh Hospital DSFH, Jeddah 21461, Saudi Arabia.
- Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah 22252, Saudi Arabia.
- Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.
- Clinical and Administrative Pharmacy Sciences, College of Pharmacy, Howard University, Washington, DC 20059, United States.
Zitieren
APA
Alqifari, S. F., Alkomi, O., Esmail, A., Alkhawami, K., Yousri, S., Muqresh, M. A., Alharbi, N., Khojah, A. A., Aljabri, A., Allahham, A., Prabahar, K., Alshareef, H., Aldhaeefi, M., Alrasheed, T., Alrabiah, A., & AlBishi, L. A. (2024). Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus. World Journal of Diabetes, 15(3), 331-347. https://doi.org/10.4239/wjd.v15.i3.331
Vancouver
Alqifari SF, Alkomi O, Esmail A, Alkhawami K, Yousri S, Muqresh MA, et al. Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus. World Journal of Diabetes. 2024;15(3):331-347. doi:10.4239/wjd.v15.i3.331
BibTeX
@article{Alqifari2024,
author = {Alqifari, Saleh Fahad and Alkomi, Omar and Esmail, Abdullah and Alkhawami, Khadijeh and Yousri, Shahd and Muqresh, Mohamad Ayham and Alharbi, Nawwarah and Khojah, Abdullah A and Aljabri, Ahmed and Allahham, Abdulrahman and Prabahar, Kousalya and Alshareef, Hanan and Aldhaeefi, Mohammed and Alrasheed, Tariq and Alrabiah, Ali and AlBishi, Laila A},
title = {Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus},
journal = {World Journal of Diabetes},
year = {2024},
volume = {15},
number = {3},
pages = {331--347},
doi = {10.4239/wjd.v15.i3.331}
}
EUVIMED